Since interleukin-1 receptor and TLR4 signaling triggers MYD88 innate immune signal transduction adaptor (MyD88) activation cascade in monocytes, the effect of levantinib could be not only on hepatoma cells, but also on monocytes. This evidence concerns the gene TLR4 and hepatocellular carcinoma.